MIM
VYGR icon

MetLife Investment Management’s Voyager Therapeutics VYGR Stock Holding History

MetLife Investment Management’s Portfolio VYGR Stock Details VYGR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$100K Buy
28,674
+2,561
+10% +$9.71K ﹤0.01% 2775
2026
Q1 		$101K Buy
26,113
+10,905
+72% +$42.9K ﹤0.01% 2537
2025
Q4 		$59.8K Sell
15,208
-11,545
-43% -$51.1K ﹤0.01% 2712
2025
Q3 		$125K Sell
26,753
-78
-0.3% -$282 ﹤0.01% 2552
2025
Q2 		$83.4K Buy
26,831
+5,919
+28% +$19.1K ﹤0.01% 2630
2025
Q1 		$70.7K Sell
20,912
-6,123
-23% -$28.6K ﹤0.01% 2644
2024
Q4 		$153K Hold
27,035
– – ﹤0.01% 2430
2024
Q3 		$158K Hold
27,035
– – ﹤0.01% 2409
2024
Q2 		$214K Buy
27,035
+8,766
+48% +$73.5K ﹤0.01% 2201
2024
Q1 		$170K Buy
18,269
+1,448
+9% +$12.2K ﹤0.01% 2284
2023
Q4 		$142K Hold
16,821
– – ﹤0.01% 2423
2023
Q3 		$130K Hold
16,821
– – ﹤0.01% 2451
2023
Q2 		$193K Buy
+16,821
New +$174K ﹤0.01% 2294
2020
Q4 		– Sell
-10,649
Closed -$114K – 2314
2020
Q3 		$114K Hold
10,649
– – ﹤0.01% 2161
2020
Q2 		$134K Hold
10,649
– – ﹤0.01% 2114
2020
Q1 		$97.4K Hold
10,649
– – ﹤0.01% 2094
2019
Q4 		$149K Hold
10,649
– – ﹤0.01% 2137
2019
Q3 		$183K Hold
10,649
– – ﹤0.01% 2001
2019
Q2 		$290K Sell
10,649
-21,298
-67% -$487K ﹤0.01% 1807
2019
Q1 		$612K Buy
31,947
+21,298
+200% +$277K ﹤0.01% 1948
2018
Q4 		$100K Hold
10,649
– – ﹤0.01% 2301
2018
Q3 		$201K Hold
10,649
– – ﹤0.01% 2077
2018
Q2 		$208K Buy
10,649
+2,964
+39% +$58.6K ﹤0.01% 1903
2018
Q1 		$144K Hold
7,685
– – ﹤0.01% 2055
2017
Q4 		$128K Buy
+7,685
New +$132K ﹤0.01% 2146

Other funds holding VYGR

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
AC
Armistice Capital New York $8.17B AUM 68.82% 1-Year Est. Return
VPC
Vestal Point Capital New York $4.28B AUM 239% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
OM
Opaleye Management Boston, Massachusetts $1.1B AUM 197.64% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return

MetLife Investment Management's VYGR Position: Q2 2026 in Review

MetLife Investment Management increased its Voyager Therapeutics (VYGR) stake by 9.8% in Q2 2026, buying an estimated $9.71K and bringing the position to 28,674 shares worth $100K. The position accounts for ﹤0.01% of the portfolio, ranked #2775.

MetLife Investment Management first reported a position in VYGR in Q4 2017 and has held it in 25 quarters since. The position peaked at $612K in Q1 2019. 136 funds tracked by Wall St. Rank hold VYGR as of Q2 2026.

  • MetLife Investment Management held 28,674 shares of Voyager Therapeutics worth $100K as of Q2 2026.
  • MetLife Investment Management bought 2,561 Voyager Therapeutics shares in Q2 2026, an estimated $9.71K.
  • Voyager Therapeutics made up ﹤0.01% of MetLife Investment Management's portfolio in Q2 2026, its #2775 holding.
  • MetLife Investment Management first reported a position in Voyager Therapeutics in Q4 2017 and has held it in 25 quarters since.
  • MetLife Investment Management's Voyager Therapeutics position peaked at $612K in Q1 2019.
  • 136 funds tracked by Wall St. Rank held Voyager Therapeutics as of Q2 2026.

Based on MetLife Investment Management's 13F filing for Q2 2026, filed 14 Aug 2026.